Microparticles and nanoparticles as delivery systems for DNA vaccines

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 20, Issue 2-3, 2003, Pages 103-137

  Cui, Zhengrong ^a   Mumper, Russell J ^a  

^a University of Kentucky   (United States)

Author keywords

Adjuvant; Dendritic cell; Genetic vaccine; Immunization; Microemulsion; Polylactide co glycolide

Indexed keywords

3 (N,N DIMETHYLAMINOETHANE)CARBONYL CHOLESTEROL; ALGINIC ACID; BETA GALACTOSIDASE; CAPSID PROTEIN; CARBOXYMETHYLCELLULOSE; CETRIMIDE; CHITOSAN; CHOLERA TOXIN; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DNA VACCINE; DRUG CARRIER; EMULSIFYING AGENT; ENVELOPE PROTEIN; INSECT PROTEIN; LIPID A; LIPOSOME; LUCIFERASE; MANNAN; NANOPARTICLE; NUCLEOCAPSID PROTEIN; OCTADECYLAMINE; PEPTIDE VSV N52 59; PHOSPHATIDYLETHANOLAMINE; PLASMID DNA; POLYETHYLENEIMINE; POLYGLACTIN; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIROSOME; VIRUS PROTEIN; ZYC 101;

ANTIGEN EXPRESSION; CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; EMULSION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; MALARIA; MICROEMULSION; NONHUMAN; REVIEW; TUBERCULOSIS; VESICULAR STOMATITIS VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOTECHNOLOGY; PARTICLE SIZE; PLASMIDS; VACCINES, DNA;

EID: 0141894038     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v20.i23.10     Document Type: Review

References (132)

1. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D, Bronson R, Greene MF, McClure HM, Martin LN, Ruprecht RM. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999; 5:194-203.
2. Plotkin SL, Plotkin SA. A short history of vaccine. In: Plotkin SA, Mortimer Jr. EA, editors. Vaccine. 2 ed. Philadelphia PA: WB Saunders, 1988.
3. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant: past experiences and new directions. In: Powell MF, Newman MJ, editors. Vaccine design: the subunit and adjuvant approach. New York. Plenum, 1995.
4. Lesinski SB, Westerink MA. Vaccine against polysaccharide antigens. Curr Drug Targets Infect Disord 2001; 1:325-334.
5. O'Hagan DT, MacKichan ML, Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomolec Eng 2001; 18:69-85.
6. Will H, Cattaneo R, Koch HG, Darai G, Schaller H, Schellekens H, van Eerd PM, Deinhardt F. Cloned HBV DNA causes hepatitis in chimpanzees. Nature 1982; 299:740-742.
7. Dubensky TW, Campbell BA, Villarreal LP. Direct transfection of viral and plasmid DNA into the liver or spleen of mice. Proc Natl Acad Sci USA 1984; 81:7529-7533.
8. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-1468.
9. Tang DT, Devit M, Johnston SA. Genetic immunization is a simple model for eliciting an immune response. Nature 1992; 356:152-154.
10. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-1749.
11. Fynan EF, Webster RG, Fuller FH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 1993; 90:11478-11482.
12. Mumper RJ, Ledebur HC. Dendritic cell delivery of plasmid DNA: application for controlled genetic immunization. Mol Biotech 2001; 19:79-95.
13. Krieg AM, Yi AK, Waldschmidt YJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374:546-549.
14. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, Jones TR, Hobart P, Margalith M, Ng J, Weiss WR, Sedegah M, de Taisne C, Norman JA, Hoffman SL. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282:476-480.
15. Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, Sandstrom E, Wahren B. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998; 351:1320-1325.
16. Wang R, Epstein J, Baraceros FM, Gorak EJ, Charoenvit Y, Carucci DJ, Hedstrom RC, Rahardjo N, Gay T, Hobart P, Stout R, Jones TR, Richie TL, Parker SE, Doolan DL, Norman J, Hoffman, SL. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA 2001; 98:10817-10822.
17. + T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2001;19:764-778.
18. Alpar HO. Current status of DNA vaccines and their route of administration. Crit Rev Ther Drug Carrier Syst 2002; 19:307-383.
19. Ramon G. Procedres pour acroitre la production des antitoxins. Ann Inst Pasteur 1926; 40:1-10.
20. Cox JC, Coulter AR. Adjuvants-a classification and review of their modes of action. Vaccine 1997; 15:248-256.
21. Lycke N. The mechanism of cholera toxin adjuvanticity. Res Immunol 1997; 148:504-520.
22. Heath AW. Cytokines as immunological adjuvants. In: Powell MF, Newman MJ, editors. Vaccine design: the subunit and adjuvant approach. New York: Plenum, 1995.
23. Claassen E, de Leeuw W, de Greeve P, Hendriksen C, Boersman W. Freund's complete adjuvant: an effective but disagreeable formula. Res Immunol 1992; 143:478-483.
24. Morein B, Fossum C, Lovgren K, Hoglund S. The ISCOMS-a modern approach to vaccines. Semin Virol 1999; 1:49-55.
25. Singh M, Carlson JR, Briones M, Ugozzoli M, Kazzaz J, Barackman J, Ott G, O'Hagan D. A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine 1998; 16:1822-1827.
26. Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc Natl Acad Sci USA 2000; 97:811-816.
27. Alving CR. Liposomes as carrier of antigens and adjuvants. J Immunol Methods 1991; 140:1-13.
28. Moser CA, Speaker TJ, Offit PA. Effect of microencapstdation on immunogenicity of a bovine herpes virus glycoprotein and inactivated influenza virus in mice. Vaccine 1997; 15:1767-1772.
29. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000; 50:161-177.
30. rd Annual Conference on Vaccine Research. April 30-May 2, Washington, DC, 2000.
31. Schijns VE. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 2000; 12:456-463.
32. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9:271-296.
33. Raychaudhuri S, Rock KL. Fully mobilizing host defense: building better vaccines. Nat Biotech 1998; 16:1025-1031.
34. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Ann Rev Immunol 2000; 18:927-974.
35. Takashima A, Morita A. Dendritic cells in genetic immunization. J Leuk Biol 1999; 66:350-356.
36. Shedlock DJ, Weiner DB. DNA vaccination: antigen presentation and the induction of immunity. J Leuk Biol 2000; 68:793-806.
37. Pachuk CJ, McCallus DE, Weiner DB, Satishchandran C. DNA vaccines-challenges in delivery. Curr Opin Mol Ther 2000; 2:188-198.
38. Barnes AG, Barnfield C, Brew R, Klavinskis LS. Recent developments in mucosal delivery of pDNA vaccines. Curr Opin Mol Ther 2000; 2:87-93
39. Hilleman MR. A simplified vaccinologists vaccinology and the pursuit of a vaccine against AIDS. Vaccine 1998; 16:778-793.
40. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-252.
41. Parham P. The immune system. London: Current Trends, 2000.
42. Yang Y, Sempe P, Peterson PA. Molecular mechanisms of class I major histocompatibility complex antigen processing and presentation. Immunol Res 1996; 15:208-233.
43. Castellinon F, Zhong G, Germain RN. Antigen presentation by MHC class II molecules, invariant chain function, protein trafficking and the molecular basis of diverse determinant capture. Hum Immunol 1997; 54:156-169.
44. Corr M, Lee D, Carson DA, Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 1996; 184:1555-1560.
45. Iwasaki A, Torres CAT, Ohashi PS, Robison HL. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J Immunol 1997; 159:11-14.
46. Liu MA. The immunologists grail: vaccines that generate cellular immunity. Proc Natl Acad Sci USA 1997; 94:10496-10498.
47. Abbas AK, Lichtman AH, Pober JS. Cellular and molecular immunology. Toronto: Saunders, 1997.
48. Nixon DF, Hioe C, Chen PD, Bian Z, Kuebler P, Li ML, Qiu H, Li XM, Singh M, Richardson J, McGee P, Zamb T, Koff W, Wang CY, O'Hagan D. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 1996; 14:1523-1530.
49. Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 1995; 12:1-99.
50. Putney SD, Burke PA. Improving protein therapeutics with sustained-release formulations. Nat Biotechnol 1998; 16:153-157.
51. Maloy KJ, Donachie AM, O'Hagan DR, Mowat MA. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 1994; 81:661-667.
52. Kreuter J, Speiser PP. New adjuvants on a polymethylmethacrylate base. Infect Immun 1976; 13:204-210.
53. O'Hagan D, Singh M, Ugozzoli M, Wild C, Barnett S, Chen M, Schaefer M, Doe B, Otten GR, Ulmer JB. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J Virol 2001; 75:9037-9043.
54. Singh M, Vajay M, Gardner J, Briones M, O'Hagan D. Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine 2002; 20:594-602.
55. Singh M, Ott G, Kazzaz J, Ugozzoli M, Briones M, Donnelly J, O'Hagan DT. Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm Res 2001; 18:1476-1479.
56. Luo Y, O'Hagan D, Zhou H, Singh M, Ulmer J, Reisfeld RA, Primus FJ, Xiang R. Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice. Vaccine 2003; 21:1938-1947.
57. Haensler J, Verdelet C, Sanchez V, Girerd-Chambaz T, Bonnin A, Trannoy E, Krishnan S, Meulien P. Intradermal DNA immunization by using jet-injectors in mice and monkey. Vaccine 1999; 26:628-638.
58. Denis-Mize KS, Dupuis M, MacKichan ML, Singh M, Doe B, O'Hagan D, Ulmer JB, Donnelly JJ, McDonald DM, Ott G. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther 2000; 7:2105-2112.
59. Oster CG, Kissel T. Cationic nanoparticles consisting of polyethylenimine and PLGA as parenteral carriers for DNA vaccination. Globalization of Pharmaceutics Education Network. November 6-8, Ann Arbor, MI, 2002 poster 23.
60. Jones Dh, Corris S, McDonald S, Clegg JCS, Farrar GH. Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 1997; 15:814-817.
61. Russell-Jones GI. Oral vaccine delivery. J Control Release 2002; 65:49-54.
62. Jones DH, Clegg JC, Farrar GH. Oral delivery of micro-encapsulated DNA vaccines. Dev Biol Stand 1998; 92:149-155.
63. Chen SC, Jones DH, Fynan EF, Farrar GH, Christopher J, Clegg S, Greenberg HB, Herrmann JE. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 1998; 72:5757-5761.
64. Herrmann JE, Chen SC, Jones DH, Tinsley-Bown A, Fyann EF, Greenberg HB, Farrar GH. Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microspheres. Virology 1999; 259:148-153.
65. Kaneko H, Bednarek I, Wierzbicki A, Kiszka I, Dmochowski M, Wasik TJ, Kaneko Y, Kozbor D. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology 2000; 267:8-16.
66. Wierzbicki A, Kiszka I, Kaneko H, Kmieciak D, Wasik TJ, Gzyl J, Kaneko Y, Kozbor D. Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelop glycoprotein. Vaccine 2002; 20:1295-1307.
67. Fooks AR, Sharpe SA, Shallcross JA, Clegg JC, Cranage MP. Induction of immunity using oral DNA vaccines expressing the measles virus nucleocapsid protein. Dev Biol (Basel) 2000; 104:65-71.
68. Langer R, Cleland JL, Hanes J. New advances in microsphere-based single-dose vaccines. Adv Drug Deliv Rev 1997; 28:97-119.
69. Hedley ML, Curley J, Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med 1998; 4:365-368.
70. Lunsford L, McKeever U, Eckstein V, Hedley ML. Tissue distribution and persistence in mice of plasmid DNA encapsulated in a PLGA-based microsphere delivery vehicle. J Drug Target 2000; 8:39-50.
71. Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, Thatcher J, Weinberg V, Wilson J, Darragh T, Jay N, Da Costa M, Palefsky JM. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 2002; 8:1028-1037.
72. McKeever U, Barman S, Hao T, Chambers P, Song S, Lunsford L, Hsu YY, Roy K, Hedley ML. Protective immune responses elicited in mice by immunization with formulations of poly(lactide-co-glycolide) microparticles. Vaccine 2002; 20:1524-2531.
73. Ando S, Putnam D, Pack DW, Langer R. PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J Pharm Sci 1999; 88:126-130
74. Walter E, Moelling K, Pavlovic J, Merkle HP. Microencapsulation of DNA using poly(DL-lactide-glycolide): stability issues and release characteristics. J Control Release 1999; 61:361-374.
75. Mittal SK, Aggarwal N, Sailaja G, van Olphen A, HogenEsch H, North A, Hays J, Moffatt S. Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine 2001; 19:253-263.
76. Douglas SJ, Davis SS, Illum L. Nanoparticles in drug delivery. Crit Rev Ther Drug Carrier Syst 1987; 3:233-261.
77. Moghimi SM, Hawley AE, Christy NM, Cray T, Illum L, Davis SS. Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. FEBS Lett 1994; 344:25-30.
78. Hawley AE, Illum L, Davis SS. Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm Res 1997; 14:657-661.
79. Hawley AE, Illum L, Davis SS. Lymph node localization of biodegradable nanospheres surface modified with poloxamer and poloxamine block co-polymers. FEBS Lett 1997; 400:319-323.
80. Cui Z, Mumper RJ. Dendritic cell-targeted genetic vaccines engineered from novel microemulsion precursors. Mol Ther 2001; 3:S352.
81. Cui Z, Mumper RJ. Genetic immunization using nanoparticles engineered from microemulsion precursors. Pharm Res 2002; 19:939-946.
82. Cui Z, Mumper RJ. Topical immunization using nanoengineered genetic vaccines. J Control Release 2002; 81:173-184.
83. Cui Z, Mumper RJ. Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses. J Pharm Pharmacol 2002; 54:1195-1203.
84. Cui Z, Baizer L, Mumper RJ. Intradermal immunization with novel pDNA-coated nanoparticles via a needle-free injection device. J Biotechnol 2003; 102:105-115.
85. Cui Z, Mumper RJ. The effect of co-administration of adjuvants with a nanoparticle-based genetic vaccine delivery system on the resulting immune responses. Eur J Pharm Biopharm 2003; 55:11-18.
86. Shi Z, Curiel DT, Tang DC. DNA-based non-invasive vaccination onto the skin. Vaccine 1999; 17:2136-2141.
87. Fan H, Lin Q, Morrissey GR, Khavari PA. Immunization via hair follicles by topical application of naked DNA to normal skin. Nat Biotechnol 1999; 17:870-872.
88. Tang DC, Shi Z, Curiel DT. Vaccination onto bare skin. Nature 1997; 388:729-730.
89. Cui Z, Fountain W, Clark M, Jay M, Mumper RJ. Novel ethanol-in-fluorocarbon microemulsions for topical genetic immunization. Pharm Res 2003; 20:16-23.
90. Mumper RJ, Cui Z, Oyewumi MO. Nanotemplate engineering of cell specific nanoparticles. In: Texter J, editor. Surface modification. J Dispersion Sci Tech 2003; 24:569-588.
91. MacLaughlin FC, Mumper RJ, Wang J, Tagliaferri JM, Gill I, Hinchcliffe M, Rolland AP. Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J Control Release 1998; 56:259-272.
92. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci 2001; 14:201-207.
93. Mumper RJ, Wang JJ, Claspell JM, Rolland AP. Novel polymeric condensing carriers for gene delivery. Proceedings of the International Symposium on Controlled Release Bioactive Materials. Seattle, Washington. July 30-August 2, 1995.
94. Collins PL, McIntosh K, Chanock RM. In: Fields BN, Knipe DM, Howley PM, editors. Field Virology. Philadelphia: Lippincott-Raven, 1996.
95. Iqbal M, Lin W, Jabbal-Gill I, Davis SS, Steward MW, Illum L. Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 2003; 21:1478-1485.
96. Cui Z, Mumper RJ. Chitosan-based nanoparticles for topical genetic immunization. J Control Release 2001; 75:409-419.
97. Roy K, Mao H, Leong KW. DNA-chitosan nanospheres: transfection efficiency and cellular uptake, Proceedings of the International Symposium on Controlled Release and Bioactive Materials. 1997; 24:673.
98. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generate immunologic protection in a murine model of peanut allergy. Nat Med 1999; 5:387-91.
99. Kumar M, Behera AK, Lockey RF, Zhang J, Bhullar G, De La Cruz CP, Chen LC, Leong KW, Huang SK, Mohapatra SS. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther 2002; 13:1415-1425.
100. Tischer BK, Schumacher D, Beer M, Beyer J, Teifke JP, Osterrieder K, Wink K, Zelnik V, Fehler F, Osterrieder N. A DNA vaccine containing an infectious Marek's disease virus genome can confer protection against tumorigenic Marek's disease in chickens. J Gen Virol. 2002; 83:2367-2376.
101. Bangham AD. Lipid bilayers and biomembranes. Annu Rev Biochem 1972; 41:753-776.
102. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol Today 1990; 11:89-97.
103. Yokoyama M, Zhang J, Whitton JL. DNA immunization: effects ofvehicle and route of administration on the induction of protective antiviral immunity. FEMS Immunol Med Microbiol 1996; 14:221-230.
104. Gregoriadis G, Saffie R, de Souza JB. Liposome-mediated DNA vaccination. FEBS Lett 1997; 402:107-110.
105. Perrie Y, Frederik PM, Gregoriadis G. Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine 2001; 19:3301-3310.
106. Bacon A, Caparros-Wanderley W, Zadi B, Gregoriadis G. Induction of a cytotoxic T lymphocyte (CTL) response to plasmid DNA delivered via lipodine liposomes. J Liposome Res 2002; 12:173-183.
107. Perrie Y, Obrenovic M, McCarthy D, Gregoriadis G. Liposome (lipodine)-mediated DNA vaccination by the oral route. J Liposome Res 2002; 12:185-197.
108. Okamoto T, Kaneda Y, Yuzuki D, Huang SK, Chi DD, Hoon DS. Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine. Gene Ther 1997; 4:969-976.
109. Zhou WZ, Kaneda Y, Huang S, Morishita R, Hoon D. Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine. Gene Ther 1999; 6:1768-1773.
110. Tanaka M, Kaneda Y, Fujii S, Yamano T, Hashimoto K, Huang SK, Hoon DS. Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma. Mol Ther 2002; 5:291-299.
111. Lanuti M, Rudginsky S, Force SD, Lambright ES, Siders WM, Chang MY, Amin KM, Kaiser LR, Scheule RK, Albelda SM. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res 2000; 60:2955-2963.
112. Ishii N, Fukushima J, Kaneko T, Okada E, Tani K, Tanaka SI, Hamajima K, Xin KQ, Kawamoto S, Koff W, Nishioka K, Yasuda T, Okuda K. Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1997; 13:1421-1428.
113. Sha Z, Vincent MJ, Compans RW. Enhancement of mucosal immune responses to the influenza virus DNA protein by alternative approaches to DNA immunization. Immunobiology 1999; 200:21-30.
114. Wong JP, Zabielski MA, Schmaltz FL, Brownlee GG, Bussey LA, Marshall K, Borralho T, Nagata LP. DNA vaccination against respiratory influenza virus infection. Vaccine 2001; 19:2461-2467.
115. Harpin S, Hurley DJ, Mbikay M, Talbot B, Elazhary Y. Vaccination of cattle with a DNA plasmid encoding the bovine viral diarrhea virus major glycoprotein E2. J Gen Virol 1999; 80:3137-3144.
116. Okada E, Sasaki S, Ishii N, Aoki I, Yasuda T, Nishioka K, Fukushima J, Miyazaki J, Wahren B, Okuda K. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 1997; 159:3638-3647.
117. Klavinskis LS, Gao L, Barnfield C, Lehner T, Parker S. Mucosal immunization with DNA-liposome complexes. Vaccine 1997; 15:818-820.
118. Wierzbicki A, Kiszka I, Kaneko H, Kmieciak D, Wasik TJ, Gzyl J, Kaneko Y, Kozbor D. Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelope glycoprotein. Vaccine 2002; 20:1295-1307.
119. Toda S, Ishii N, Okada E, Kusakabe KI, Arai H, Hamajima K, Gorai I, Nishioka K, Okuda K. HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody. Immunol 1997; 92:111-117.
120. Bramwell VW, Eyles JE, Somavarapu S, Alpar HO. Liposome/DNA complexes coated with biodegradable PLA improve immune responses to plasmid encoding hepatitis B surface antigen. Immunobiologoy 2002; 106:412-418.
121. Dzau VJ, Mann MJ, Morishita R, Kaneda Y. Fusigenic viral liposomes for gene therapy in cardiovascular diseases. Proc Natl Acad Sci USA 1996; 93:11421-11425.
122. Cusi MG, Zurbriggen R, Valassina M, Bianchi S, Durrer P, Valensin PE, Donati M, Gluck R. Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity. Virology 2000; 277:111-118.
123. Correale P, Cusi MG, Sabatino M, Micheli L, Pozzessere D, Nencini C, Valensin PE, Petrioli R, Giorgi G, Zurbriggen R, Gluck R, Francini G. Tumor-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes. Eur J Cancer 2001; 37:2097-2103.
124. Papahadjopoulos D, Vail WJ, Jacobson K, Poste G. Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim Biophys Acta 1975; 394:483-491.
125. Gould-Fogerite S, Kheiri MT, Zhang F, Wang Z, Scolpino AJ, Feketeova E, Canki M, Mannino RJ. Targeting immune response induction with cochleate and liposome-based vaccines. Adv Drug Del Rev 1998; 32:273-287.
126. ZarifL, Brois D, Chen ZW, Zhang F, Mautone A, Scolpino A, Lu R. Gould-Fogerite S, Mannino RJ. Utilization of cochleates for the delivery of genetic materials in vivo. In: Habib N, editor. Cancer gene therapy. Southborough, MA: IBC Biomedical Library, 1997.
127. Goto N, H Kato, JI Maeyama. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminum hydroxide with different physical properties. Vaccine 1997; 15:1364-1370.
128. He Q, Mitchell AR, Johnson SL, Wagner-Bartak C, Morcol T, Bell SJ. Calcium phosphate nanoparticle adjuvant. Clin Diagn Lab Immunol 2000; 7:899-903.
129. He Q, Mitchell A, Morcol T, Bell SJ. Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clin Diagn Lab Immunol 2002; 9:1021-1024.
130. Ulmer JB, DeWitt CM, Chastain M, Friedman A, Donnelly JJ, McClements WL, Caulfield MJ, Bohannon KE, Volkin DB, Evans RK. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 1999; 18:18-28.
131. Ott G, Singh M, Kazzaz J, Briones M, Soenawan E, Ugozzoli M, O'Hagan DT. A cationic submicron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines. J Control Release 2002; 79:1-5.
132. Ott G, Radhakrishnan R, Fang JF, Hora MS. The adjuvant MF 59: a 10-year perspective. In: O'Hagan D, editor. Vaccine adjuvants. Clifton, NJ: Humana Press, 2000.